The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 29, 2021
Filed:
Feb. 06, 2018
Applicant:
Dana-farber Cancer Institute, Inc., Boston, MA (US);
Inventors:
James Bradner, Weston, MA (US);
Justin Roberts, Cambridge, MA (US);
Behnam Nabet, Boston, MA (US);
Georg Winter, Vienna, AT;
Andrew J. Phillips, Arlington, MA (US);
Timothy Heffernan, Sugar Land, TX (US);
Dennis Buckley, Jamaica Plain, MA (US);
Assignee:
DANA-FARBER CANCER INSTITUTE, INC., Boston, MA (US);
Attorneys:
Primary Examiner:
Int. Cl.
CPC ...
A61K 35/17 (2015.01); A61K 35/12 (2015.01); C07K 16/28 (2006.01); C12N 5/10 (2006.01); C12N 15/11 (2006.01); C07K 16/00 (2006.01); A61K 31/4525 (2006.01); A61K 31/4545 (2006.01); A61K 31/4985 (2006.01); A61K 31/506 (2006.01); A61K 31/519 (2006.01); A61K 31/551 (2006.01); A61K 31/575 (2006.01); C07K 14/725 (2006.01); C07K 14/705 (2006.01); A61K 31/5513 (2006.01); A61K 31/58 (2006.01); C07K 14/47 (2006.01); C12N 15/90 (2006.01); A61K 48/00 (2006.01);
U.S. Cl.
CPC ...
C12N 15/11 (2013.01); A61K 31/4525 (2013.01); A61K 31/4545 (2013.01); A61K 31/4985 (2013.01); A61K 31/506 (2013.01); A61K 31/519 (2013.01); A61K 31/551 (2013.01); A61K 31/5513 (2013.01); A61K 31/575 (2013.01); A61K 31/58 (2013.01); A61K 35/17 (2013.01); C07K 14/47 (2013.01); C07K 14/7051 (2013.01); C07K 14/70517 (2013.01); C07K 14/70521 (2013.01); C07K 16/00 (2013.01); C07K 16/2863 (2013.01); C12N 15/907 (2013.01); A61K 48/00 (2013.01); A61K 2035/122 (2013.01); C07K 2317/622 (2013.01); C07K 2319/03 (2013.01); C07K 2319/20 (2013.01); C07K 2319/95 (2013.01); C12N 2310/20 (2017.05); C12N 2800/80 (2013.01);
Abstract
This invention is in the area of compositions and methods for regulating chimeric antigen receptor immune effector cell, for example T-cell (CAR-T), therapy to modulate associated adverse inflammatory responses, for example, cytokine release syndrome and tumor lysis syndrome, using targeted protein degradation.